{"id":30711,"date":"2024-12-31T14:00:00","date_gmt":"2024-12-31T08:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30711"},"modified":"2024-12-31T11:20:26","modified_gmt":"2024-12-31T05:50:26","slug":"pharma-news-for-precigen-bms-sapience","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience","title":{"rendered":"FDA Approves Opdivo Qvantig\u2122 for Solid Tumors; Nuvation Bio\u2019s Taletrectinib NDA Accepted for ROS1-Positive NSCLC; HKBU\u2019s Aptamer for X-Linked Hypophosphatemia Gets FDA Orphan Designation; Sapience\u2019s ST316 Receives FDA Orphan Status for FAP; Precigen Submits BLA for PRGN-2012 in RRP"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1e01fc4e8e7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1e01fc4e8e7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\/#FDA_Approves_Opdivo_Qvantig%E2%84%A2_nivolumab_and_hyaluronidase-nvhy_for_Subcutaneous_Use_in_Adult_Solid_Tumors\" >FDA Approves Opdivo Qvantig\u2122 (nivolumab and hyaluronidase-nvhy) for Subcutaneous Use in Adult Solid Tumors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\/#FDA_Accepts_Nuvation_Bios_Taletrectinib_NDA_for_Advanced_ROS1-Positive_NSCLC\" >FDA Accepts Nuvation Bio\u2019s Taletrectinib NDA for Advanced ROS1-Positive NSCLC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\/#HKBUs_Aptamer_for_X-Linked_Hypophosphatemia_Receives_Orphan_and_Rare_Pediatric_Disease_Designations_from_FDA\" >HKBU&#8217;s Aptamer for X-Linked Hypophosphatemia Receives Orphan and Rare Pediatric Disease Designations from FDA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\/#FDA_Grants_Orphan_Drug_Status_to_Sapience_Therapeutics_ST316_for_Familial_Adenomatous_Polyposis\" >FDA Grants Orphan Drug Status to Sapience Therapeutics&#8217; ST316 for Familial Adenomatous Polyposis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\/#Precigen_Submits_BLA_for_PRGN-2012_in_Recurrent_Respiratory_Papillomatosis_Requests_FDA_Priority_Review\" >Precigen Submits BLA for PRGN-2012 in Recurrent Respiratory Papillomatosis, Requests FDA Priority Review<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-opdivo-qvantig-nivolumab-and-hyaluronidase-nvhy-for-subcutaneous-use-in-adult-solid-tumors\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Opdivo_Qvantig%E2%84%A2_nivolumab_and_hyaluronidase-nvhy_for_Subcutaneous_Use_in_Adult_Solid_Tumors\"><\/span>FDA Approves Opdivo Qvantig\u2122 (nivolumab and hyaluronidase-nvhy) for Subcutaneous Use in Adult Solid Tumors<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bristol Myers Squibb<\/strong> has received <strong>FDA&nbsp; approval<\/strong> for<strong> Opdivo Qvantig\u2122 (nivolumab and hyaluronidase-nvhy) injection <\/strong>for subcutaneous use. This innovative product is a combination of nivolumab and recombinant human hyaluronidase (rHuPH20). It is now approved for <strong>most adult solid tumor indications<\/strong> where Opdivo is used, including monotherapy, maintenance therapy post-Opdivo plus Yervoy\u00ae (ipilimumab), or in combination with chemotherapy or cabozantinib. This approval follows the Phase III CheckMate-67T trial, demonstrating comparable efficacy, safety, and pharmacokinetics to intravenous (IV) Opdivo.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cSubcutaneous nivolumab offers patients a new treatment option that combines consistent efficacy with a shorter, patient-centric administration process,\u201d said Dr. Saby George, MD, FACP, from Roswell Park Comprehensive Cancer Center. \u201cThe ability to deliver treatment in just a few minutes opens the door for more flexible care, tailored to the needs of patients and their healthcare providers.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Opdivo Qvantig provides a quicker administration alternative, delivering immunotherapy in just three to five minutes compared to the 30-minute infusion time for IV Opdivo. The trial results showed a slightly higher overall response rate (ORR) of 24% with Opdivo Qvantig compared to 18% with IV Opdivo, along with non-inferior pharmacokinetics and a comparable safety profile. This new method offers greater flexibility, allowing treatment closer to home and reducing preparation steps for providers.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAt Bristol Myers Squibb, we remain dedicated to improving every aspect of the patient care journey,\u201d stated Adam Lenkowsky, executive vice president and chief commercialization officer. \u201cThis approval adds another layer of flexibility and convenience to Opdivo\u2019s proven track record in immunotherapy, reinforcing our commitment to patient-centric innovation and care.\u201dFDA Accepts Nuvation Bio&#8217;s Taletrectinib NDA for Advanced ROS1-Positive Non-Small Cell Lung Cancer<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-accepts-nuvation-bio-s-taletrectinib-nda-for-advanced-ros1-positive-nsclc\"><span class=\"ez-toc-section\" id=\"FDA_Accepts_Nuvation_Bios_Taletrectinib_NDA_for_Advanced_ROS1-Positive_NSCLC\"><\/span>FDA Accepts Nuvation Bio\u2019s Taletrectinib NDA for Advanced ROS1-Positive NSCLC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Nuvation Bio Inc. has announced the <strong>FDA\u2019s acceptance<\/strong> of its <strong>New Drug Application (NDA)<\/strong> for <strong>taletrectinib<\/strong>, a next-generation <strong>ROS1 tyrosine kinase inhibitor (TKI)<\/strong>. The investigational therapy targets advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">ROS1-positive <strong>non-small cell lung cancer (NSCLC)<\/strong><\/a><strong>,<\/strong> regardless of <strong>prior treatment<\/strong>. The FDA has granted Priority Review to the application, setting a Prescription Drug User Fee Act (PDUFA) goal date of <strong>June 23, 2025. <\/strong>This designation highlights the potential of taletrectinib to address the significant unmet needs for patients with ROS1-positive NSCLC. Notably, taletrectinib has also received Orphan Drug Designation and Breakthrough Therapy Designation, making it the only ROS1 TKI in development with such recognition.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are thrilled to reach this important milestone for taletrectinib, a significant step forward for people living with ROS1-positive NSCLC who urgently need new treatment options,\u201d said Dr. David Hung, Founder, President, and CEO of Nuvation Bio. \u201cWith data from over 300 patients\u2014the largest ROS1-positive NSCLC dataset to date supporting an original NDA\u2014taletrectinib has demonstrated the potential to deliver durable and meaningful benefits.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The NDA submission is supported by <strong>pooled results from the pivotal Phase II TRUST-I and TRUST-II studies, <\/strong>previously presented at the <strong>European Society of Medical Oncology (ESMO) Congress<\/strong> in <strong>September 2024.<\/strong> These studies highlighted taletrectinib\u2019s potential to offer significant clinical benefits for patients, marking an advancement in the treatment of advanced ROS1-positive NSCLC.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Hung added, \u201cSince acquiring AnHeart Therapeutics earlier this year, including taletrectinib, we have executed on our plan to advance taletrectinib toward a full U.S. regulatory approval. The FDA\u2019s Priority Review reflects the strength of our clinical data and the promise taletrectinib holds for patients. As we prepare for a launch as early as mid-2025, we\u2019re taking critical steps to establish Nuvation Bio as a commercial oncology organization, reinforcing our commitment to bringing innovative therapies to patients who need them most.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hkbu-s-aptamer-for-x-linked-hypophosphatemia-receives-orphan-and-rare-pediatric-disease-designations-from-fda\"><span class=\"ez-toc-section\" id=\"HKBUs_Aptamer_for_X-Linked_Hypophosphatemia_Receives_Orphan_and_Rare_Pediatric_Disease_Designations_from_FDA\"><\/span>HKBU&#8217;s Aptamer for X-Linked Hypophosphatemia Receives Orphan and Rare Pediatric Disease Designations from FDA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A collaboration between<strong> Hong Kong Baptist University (HKBU) <\/strong>and Shanghai Sixth People&#8217;s Hospital has resulted in the development of a novel <strong>therapeutic aptamer<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-hypophosphatemia-market\"><strong>treating X-linked hypophosphatemia (XLH)<\/strong><\/a><strong>,<\/strong> a rare genetic bone disease. Originally designed to treat osteogenesis imperfecta, the aptamer has been granted <strong>Orphan Drug Designation <\/strong>and <strong>Pediatric Rare Disease Designation<\/strong> by the <strong>FDA<\/strong>, accelerating its path toward clinical use and market availability.<\/p>\n\n\n\n<p>XLH, caused by mutations in the PHEX gene, leads to poor bone mineralization, resulting in symptoms like growth retardation, limb deformities, and osteomalacia. Existing treatments face limitations, particularly due to associated cardiovascular risks. The newly developed aptamer, Apc001, targets the &#8220;loop3 domain&#8221; of the sclerostin protein, enhancing bone formation while preserving cardiovascular safety.<\/p>\n\n\n\n<p>Animal studies have shown promising results, including increased blood phosphorus levels and improved bone strength in XLH-affected models. With pilot-scale production completed and preclinical toxicological assessments underway, Apc001 is scheduled to begin clinical trials in both Mainland China and the U.S., offering hope for more effective and safer treatment options for XLH patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-grants-orphan-drug-status-to-sapience-therapeutics-st316-for-familial-adenomatous-polyposis\"><span class=\"ez-toc-section\" id=\"FDA_Grants_Orphan_Drug_Status_to_Sapience_Therapeutics_ST316_for_Familial_Adenomatous_Polyposis\"><\/span>FDA Grants Orphan Drug Status to Sapience Therapeutics&#8217; ST316 for Familial Adenomatous Polyposis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Sapience Therapeutics, Inc.,<\/strong> announced that the FDA has awarded <strong>Orphan Drug Designation<\/strong> to <strong>ST316 <\/strong>for the<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-adenomatous-polyposis-market\"><strong>treatment of familial adenomatous polyposis (FAP)<\/strong><\/a>. FAP is a rare pre-malignant genetic condition that causes the growth of numerous polyps in the colon, often starting in adolescence. Without surgical intervention, the condition invariably progresses to colorectal cancer (CRC) by age 40, with no approved therapies currently available.<\/p>\n\n\n\n<p>ST316 is a first-in-class therapy designed to target the Wnt\/\u03b2-catenin signaling pathway, which is central to the development of FAP and over 80% of CRCs. Currently in a Phase II trial for CRC, ST316 inhibits \u03b2-catenin and its co-activator, BCL9, aiming to prevent the progression of FAP to malignancy and address a significant unmet medical need.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are thrilled that the FDA has granted Orphan Drug Designation to ST316 for the treatment of FAP,\u201d said Dr. Abi Vainstein-Haras, Sapience\u2019s Chief Medical Officer. \u201cThis milestone underscores the potential of ST316 to intervene in both pre-malignant and malignant diseases driven by genetic alterations in the Wnt\/\u03b2-catenin signaling pathway. Patients with FAP currently have no treatment options other than surgery and intensive monitoring to manage their disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Vainstein-Haras added, \u201cThe FDA\u2019s recognition of ST316 highlights the importance of addressing the Wnt\/\u03b2-catenin pathway in both FAP and CRC. We are committed to advancing the development of ST316 and providing a meaningful therapeutic option for patients with FAP, who face a high risk of colorectal cancer, the second-leading cause of cancer death in the United States.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Orphan Drug Designation offers several benefits, including eligibility for federal grants, tax credits for clinical research, exemption from certain FDA fees, and seven years of market exclusivity upon approval. These incentives aim to accelerate the development of treatments for rare diseases, offering hope to patients with limited options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-precigen-submits-bla-for-prgn-2012-in-recurrent-respiratory-papillomatosis-requests-fda-priority-review\"><span class=\"ez-toc-section\" id=\"Precigen_Submits_BLA_for_PRGN-2012_in_Recurrent_Respiratory_Papillomatosis_Requests_FDA_Priority_Review\"><\/span>Precigen Submits BLA for PRGN-2012 in Recurrent Respiratory Papillomatosis, Requests FDA Priority Review<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Precigen, Inc.<\/strong> has finalized the <strong>rolling submission<\/strong> of a <strong>Biologics License Application (BLA) <\/strong>to the <strong>FDA<\/strong> for <strong>PRGN-2012,<\/strong> a groundbreaking <strong>AdenoVerse\u00ae gene therapy.<\/strong> This investigational treatment targets adult <a href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-respiratory-papillomatosis-market\"><strong>patients with recurrent respiratory papillomatosis (RRP)<\/strong><\/a><strong>, <\/strong>a rare and life-altering disease caused by HPV 6 or HPV 11. The BLA is now under a 60-day FDA review, during which the agency will decide on acceptance and determine a potential Prescription Drug User Fee Act (PDUFA) action date. If granted priority review, the timeline for evaluation will be reduced to six months.<\/p>\n\n\n\n<p>PRGN-2012 holds significant potential as the first FDA-approved therapeutic for RRP, a condition marked by persistent, surgery-requiring papillomas in the respiratory tract. Current treatments involve repetitive surgeries that fail to address the root cause and significantly impact patient quality of life. Data from a pivotal Phase I\/II study, presented at the 2024 ASCO Annual Meeting, demonstrated the safety and efficacy of PRGN-2012. Primary endpoints, including safety and complete response rates (patients requiring no surgeries within 12 months of treatment), were successfully met.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe impact of this debilitating disease on patients, families, and their caregivers has been overlooked for more than half a century,\u201d said Dr. Helen Sabzevari, President and CEO of Precigen. \u201cThere is currently no approved therapy for RRP patients, and the submission of our BLA is an extremely important step in bringing the first therapy to fight this devastating disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Sabzevari further noted, \u201cWe look forward to working closely with the FDA on next steps and are excited by the potential to bring PRGN-2012 to RRP patients as quickly as possible. With our recent financial strategies enhancing our cash runway into 2026, we are well-positioned for a potential commercial launch in the second half of 2025.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>This milestone submission reflects Precigen\u2019s commitment to addressing critical unmet medical needs through innovative gene and cell therapies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Opdivo Qvantig\u2122 (nivolumab and hyaluronidase-nvhy) for Subcutaneous Use in Adult Solid Tumors Bristol Myers Squibb has received FDA&nbsp; approval for Opdivo Qvantig\u2122 (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. This innovative product is a combination of nivolumab and recombinant human hyaluronidase (rHuPH20). It is now approved for most adult solid tumor indications where [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30712,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[137,777,704,349,420,6733,979,22402,639,5789,22403,2450,22404],"industry":[17225],"therapeutic_areas":[17240,17238,17228,17243],"class_list":["post-30711","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer","tag-familial-adenomatous-polyposis","tag-fda","tag-latest-pharma-news","tag-news","tag-non-small-cell-lung-cancer","tag-non-small-cell-lung-cancer-nsclc","tag-papillomatosis","tag-pharma-news","tag-recent-pharma-news","tag-recurrent-respiratory-papillomatosis","tag-solid-tumors","tag-x-linked-hypophosphatemia","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Precigen, BMS, Sapience<\/title>\n<meta name=\"description\" content=\"Opdivo Qvantig\u2122, Nuvation Bio\u2019s Taletrectinib, HKBU\u2019s X-Linked Hypophosphatemia Aptamer, Sapience\u2019s ST316, Precigen\u2019s PRGN-2012\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Precigen, BMS, Sapience\" \/>\n<meta property=\"og:description\" content=\"Opdivo Qvantig\u2122, Nuvation Bio\u2019s Taletrectinib, HKBU\u2019s X-Linked Hypophosphatemia Aptamer, Sapience\u2019s ST316, Precigen\u2019s PRGN-2012\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-31T08:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/31111604\/pharma-news-for-precigen-bms-sapience.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Precigen, BMS, Sapience","description":"Opdivo Qvantig\u2122, Nuvation Bio\u2019s Taletrectinib, HKBU\u2019s X-Linked Hypophosphatemia Aptamer, Sapience\u2019s ST316, Precigen\u2019s PRGN-2012","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Precigen, BMS, Sapience","og_description":"Opdivo Qvantig\u2122, Nuvation Bio\u2019s Taletrectinib, HKBU\u2019s X-Linked Hypophosphatemia Aptamer, Sapience\u2019s ST316, Precigen\u2019s PRGN-2012","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-31T08:30:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/31111604\/pharma-news-for-precigen-bms-sapience.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience","name":"Pharma News | Precigen, BMS, Sapience","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/31111604\/pharma-news-for-precigen-bms-sapience.png","datePublished":"2024-12-31T08:30:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Opdivo Qvantig\u2122, Nuvation Bio\u2019s Taletrectinib, HKBU\u2019s X-Linked Hypophosphatemia Aptamer, Sapience\u2019s ST316, Precigen\u2019s PRGN-2012","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-bms-sapience#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/31111604\/pharma-news-for-precigen-bms-sapience.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/31111604\/pharma-news-for-precigen-bms-sapience.png","width":772,"height":482,"caption":"pharma-news-for-precigen-bms-sapience"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/31111604\/pharma-news-for-precigen-bms-sapience-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">papillomatosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recurrent respiratory papillomatosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">solid tumors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">X-linked hypophosphatemia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">papillomatosis<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">recurrent respiratory papillomatosis<\/span>","<span class=\"advgb-post-tax-term\">solid tumors<\/span>","<span class=\"advgb-post-tax-term\">X-linked hypophosphatemia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 31, 2024","modified":"Updated on Dec 31, 2024"},"absolute_dates_time":{"created":"Posted on Dec 31, 2024 2:00 pm","modified":"Updated on Dec 31, 2024 11:20 am"},"featured_img_caption":"pharma-news-for-precigen-bms-sapience\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30711"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30711\/revisions"}],"predecessor-version":[{"id":30713,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30711\/revisions\/30713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30712"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30711"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30711"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}